ClinicalTrials.Veeva

Menu
H

Holdsworth House Medical Practice | Sydney, Australia

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Raltegravir
Islatravir
Doravirine
Spesolimab
Ritonavir
Metformin
Emtricitabine
Tirzepatide
Gefapixant
LY3041658

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 52 total trials

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis...

Enrolling
Hidradenitis Suppurativa
Drug: Placebo
Drug: Eltrekibart

The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavi...

Active, not recruiting
HIV Infections
Drug: Lenacapavir Tablet
Drug: Zinlirvimab
Locations recently updated

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in ar...

Enrolling
Hidradenitis Suppurativa
Drug: Lutikizumab
Drug: Placebo

The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).

Enrolling
Prurigo Nodularis
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

This study is open to people with hidradenitis suppurativa (HS) who have completed another study with spesolimab (study 1368-0098 (NCT05819398) or st...

Active, not recruiting
Hidradenitis Suppurativa (HS)
Drug: Spesolimab

Evaluation of safety, tolerability and efficacy of a single intra-articular (IA) injection of PTP-001, an allogeneic placental tissue particulate, in...

Active, not recruiting
Osteoarthritis, Knee
Biological: PTP-001
Other: Placebo control

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

This study is open to adults with moderate to severe hidradenitis suppurativa (HS). The purpose of this study is to find out whether a medicine calle...

Active, not recruiting
Hidradenitis Suppurativa
Drug: Placebo matching Spesolimab Formulation 1
Drug: Placebo matching Spesolimab Formulation 2

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Olpasiran
Drug: Placebo

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus...

Active, not recruiting
HIV-1-infection
Drug: Stable Baseline Regimen
Drug: Bictegravir

This study will evaluate the safety and efficacy of a switch to MK-8591A (a fixed dose combination of doravirine and islatravir) in human immunodefic...

Active, not recruiting
HIV Infection
Drug: Placebo to BIC/FTC/TAF
Drug: Placebo to FDC DOR/ISL

Prospective clinical pilot study for subjects diagnosed with Occupational Progressive Pneumoconiosis.Subjects will be treated with Nintedanib 150mg t...

Enrolling
Silicosis
Pneumoconiosis Coal
Drug: Nintedanib 150 MG [Ofev]

Trial sponsors

K
Merck Sharp & Dohme (MSD) logo
Lilly logo
Amgen logo
Boehringer Ingelheim logo
Gilead Sciences logo
H
Pfizer logo
AbbVie logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems